Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Omkostningsnytte af to strategier for perineal rekonstruktion efter abdominoperineal resektion for anorektalt karcinom (GRECCAR-9)

2. november 2026 opdateret af: University Hospital, Toulouse

Evaluering af omkostningseffektivitet af to strategier for perineal rekonstruktion efter abdominoperineal resektion for anorektalt karcinom: Perineal fyldning med biologiske masker vs. primær perineal sårlukning

Abdominoperineal resection performed for anorectal tumors leaves a large pelvic and perineal defect causing a high rate of morbidity of the perineal wound (40 - 60 %). Biological meshes offer possibility for a new standard of perineal wound reconstruction. Perineal filling with biological mesh is expected to increase quality of life by reducing perineal morbidity.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Perineal wound problems after abdominoperineal resection (APR) in the context of cancer are frequent. These types of resection problems occur because of wound complications caused by large perineal defects. Indeed, perineal wound complications, perineal abscess, wound dehiscences, chronic fistulas and sinuses lengthen the hospital stays. Futhermore, the standardization of the surgery since the late 2000s and the extralevator technique lead a larger defect and increase i perineal complications.

Several strategies are used to decrease the complication rate. Closure by direct approximation of the pelvic muscles leads to a rate of major complication up to 57% depending on the series. Musculocutaneous flaps help to reduce this rate (16- 65%) but they generate their own morbidity, require experience and increase the costs of care. Finally, the use of biologic meshes since the beginning of 2010 seems to have improve the healing process. However, results are still variable and the only randomized study comparing direct closure and mesh closure showed no significant results at one year. Another ongoing randomized trial is comparing gluteus maximus flap to mesh closure and focusing on physical performances.

This increase in post-operative complications and their consequences causes an increase in costs. In addition, they affect the patients' quality of life and lead to a loss of productivity. From an oncological point of view, perineal scarring problems can cause a delay in the adjuvant therapeutic sequence. Few studies have highlighted the efficiency of perineal wound complications, using cost-effectiveness analyses. In order to clarify the best strategy comparing primary and mesh closure in term of cost effectiveness on perineal healing after ELAPE, we designed this randomized controlled trial.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

140

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Amiens, Frankrig
        • Amiens University Hospital
      • Angers, Frankrig
        • Angers University Hospital
      • Besançon, Frankrig
        • Besançon University Hospital
      • Bordeaux, Frankrig
        • Bordeaux University Hospital
      • Bordeaux, Frankrig, 33000
        • Clinique Tivoli Ducos
      • Caen, Frankrig
        • Caen University Hospital
      • Clermont-Ferrand, Frankrig
        • Clermont-Ferrand University Hospital
      • Grenoble, Frankrig
        • Grenoble University Hospital
      • Lille, Frankrig
        • CHRU Lille
      • Lille, Frankrig
        • Centre Oscar Lambret
      • Lyon, Frankrig
        • Lyon University Hospital
      • Marseille, Frankrig, 13915
        • Hôpitaux Universitaires de Marseille Nord
      • Marseille, Frankrig
        • Paoli Calmettes Institut
      • Nancy, Frankrig
        • Institut de Cancérologie de Lorraine
      • Nancy, Frankrig
        • Nancy University Hospital
      • Nantes, Frankrig
        • Nantes University Hospital
      • Paris, Frankrig
        • Saint-Antoine Hospital
      • Rouen, Frankrig
        • Rouen University Hospital
      • Strasbourg, Frankrig, 67200
        • Hôpital de Hautepierre (Hôpitaux Universitaires de Strasbourg)
      • Toulouse, Frankrig, 31059
        • University Hospital of Toulouse

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Age ≥ 18

  • Eastern Cooperative Oncology Group performance status score of 2 or less

  • Histologically proven rectal adenocarcinoma or anal canal epidermoïd carcinoma

  • Abdominoperineal resection indication after multidisciplinary team discussion:

    • for rectal adenocarcinoma: circumferential MRI margin equal or less than 1 mm from closest tumoral structure and a striated muscular layer (levator ani or external anal sphincter)
    • for epidermoid carcinoma: residual or recurrent tumour after chemoradiotherapy.
  • Voluntary written informed consent

  • Patients with social security insurance or equivalent social protection

Exclusion Criteria:

  • T4 tumour needing a surgical extensive resection with reconstruction by a musculocutaneous flap
  • Metastasis disease deemed unresectable with curative intent
  • Previous pelvic radiotherapy for another disease than the rectal or anal cancer
  • Immunosuppressive drugs treatment
  • Uncontrolled diabetes (glycosylated hemoglobin (HbA1c) > 8 % despite adequate therapy)
  • Patient under juridical protection.
  • Sensitivity to porcine derived products.
  • Enrolment in trial with overlapping primary endpoint.
  • Pregnant women
  • Breastfeeding women

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Dobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Arm with biological mesh

The intervention consists of perinal reconstruction using biological mesh (Cellis prosthesis from Meccellis Biotech, reference C1015E size 10x15cm)

The intervention consists of suturing a biological mesh in the pelvic floor defect. The mesh will be sutured at each side of the coccyx or distal sacrum and directly to the residual pelvic floor muscle and fascia by using interrupted or continuous hand-sewn sutures with an appropriate amount of tension. The mesh that will be used is the Cellis prosthesis from Meccellis Biotech, reference C1015E which size is 10x15cm.

Aktiv komparator: Arm with primary perineal wound closure

The intervention consists of perinal reconstruction by primary perineal wound closure

The intervention consists of stitching the ischioanal and subcutaneous fat using interrupted Vicryl sutures in one or two layers similar to primary perineal closure

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Incremental Cost-Utility Ratio (ICUR)
Tidsramme: At 12 months

The primary endpoint in this study is based on the assessment of the incremental cost-utility ratio at 1 year, from the collective perspective between biological mesh perineal reconstructions versus. primary perineal closure in patients operated for anorectal carcinoma with proven rectal adenocarcinoma or anal canal epidermoid carcinoma.

At 12 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Perineal wound healing
Tidsramme: At 1, 3, 6, 9 and 12 months

The perineal wound healing will be assessed using the Southampton wound assessment scale (6-point scale ranging from 0=normal healing to V=deep or severe wound infection)

At 1, 3, 6, 9 and 12 months
Pain intensity
Tidsramme: From date of randomization until the date of study participation end of patient, assessed up to 12 months

assessed on an 11-point Numeric Rating Scale (NRS) at baseline before surgical procedure and at least 3 times a day during hospital stay. Thereafter, patients will rate their pain intensity in a patient subject diary every day and immediately before each use of pain medication

From date of randomization until the date of study participation end of patient, assessed up to 12 months
Health related Quality of life
Tidsramme: 1 month, 3 months, 6 months, 9 months, 12 months

Health related quality of life will be assessed using the EuroQOL EQ-5D-5L questionnaire

1 month, 3 months, 6 months, 9 months, 12 months
Perineal complications
Tidsramme: Daily during hospitalization and at 1, 3, 6, 9 and 12 months after surgery

Perineal complications include:

  • Perineal wound infection defined as a swelling of the wound or surrounding tissues with purulent discharge
  • Breakdown of the perineal wound included any wound dehiscence, sinus or ulcer
  • Pelvic abscess included a fluid collection in the pelvis
  • Perineal evisceration defined by exposure of the pelvic cavity through the perineal wound
  • Perineal hernia symptomatic or not
  • Perineal sinus defined as an incomplete healing after 6 months
Daily during hospitalization and at 1, 3, 6, 9 and 12 months after surgery

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Ledende efterforsker: Etienne BUSCAIL, MD, University Hospital of Toulouse

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

7. februar 2021

Primær færdiggørelse (Faktiske)

22. april 2025

Studieafslutning (Faktiske)

22. april 2025

Datoer for studieregistrering

Først indsendt

12. juli 2016

Først indsendt, der opfyldte QC-kriterier

19. juli 2016

Først opslået (Anslået)

22. juli 2016

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

4. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

2. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • RC31/16/7940

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .